Literature DB >> 26969268

Psychometric Field Study of Hereditary Angioedema Quality of Life Questionnaire for Adults: HAE-QoL.

Nieves Prior1, Eduardo Remor2, Elia Pérez-Fernández3, Magdalena Caminoa4, Carmen Gómez-Traseira4, Francisco Gayá5, Anne Aabom6, Werner Aberer7, Stephen Betschel8, Isabelle Boccon-Gibod9, Laurence Bouillet9, Anette Bygum6, Dorottya Csuka10, Henriette Farkas10, Maria Gomide11, Anete Grumach11, Iris Leibovich12, Alejandro Malbran13, Dumitru Moldovan14, Eniko Mihaly14, Krystyna Obtulowicz15, Cecilia Perpén13, Adriane Peveling-Oberhag16, Grzegorz Porebski15, Celine Rayonne Chavannes8, Avner Reshef12, Petra Staubach16, Michaela Wiednig7, Teresa Caballero17.   

Abstract

BACKGROUND: Hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE) may affect health-related quality of life (HRQoL). A specific HRQoL questionnaire for adult patients with C1-INH-HAE, the HAE-QoL, has recently been developed in Spain.
OBJECTIVE: The objective of this study was to perform a cross-cultural validation and psychometric study of the HAE-QoL in an international setting.
METHODS: Cross-cultural adaptation of the Spanish HAE-QoL draft version and an international rating phase with experts were performed. The resultant version of the HAE-QoL, a clinical questionnaire, and Short Form 36-item Health Survey Version 2.0 (SF-36v2) were pilot tested internationally. Item reduction was based on both descriptive and exploratory factor analysis. Psychometric properties were assessed.
RESULTS: Cross-cultural adaptation of the HAE-QoL was performed in 18 countries. The draft version of the HAE-QoL was pilot tested in 332 patients, and accurate data were obtained from 290 patients from 11 countries. The reduction process resulted in a new version with 25 items and 7 dimensions (treatment difficulties, physical functioning and health, disease-related stigma, emotional role and social functioning, concern about offspring, perceived control over illness, and mental health). Strong psychometric properties were observed (Cronbach's α 0.92; test-retest reliability 0.87). Convergent validity showed mild to moderate correlations with SF-36v2 physical and mental component summaries (0.45 and 0.64, respectively) and with SF-36v2 dimensions (P < .004). HAE-QoL scores discriminated significantly among severity groups (median: asymptomatic 133.5 vs severe 84.0; P < .001); between patients with and without long-term prophylaxis (median: 101 vs 90; P = .001); and between patients with and without psychiatric and/or psychological care (median: 74 vs 103; P ≤ .001).
CONCLUSIONS: The HAE-QoL, currently available in 18 languages, showed good reliability and validity evidence.
Copyright © 2016 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adults; C1 inhibitor; Disease-specific; HAE-QoL; Hereditary angioedema; Psychometric; Quality of life; Questionnaire; SF-36v2; Validation studies

Mesh:

Year:  2016        PMID: 26969268     DOI: 10.1016/j.jaip.2015.12.010

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  18 in total

Review 1.  The symptom experience of hereditary angioedema (HAE) patients beyond HAE attacks: literature review and clinician interviews.

Authors:  Milenka Jean-Baptiste; Robbin Itzler; Subhransu Prusty; Dylan Supina; Mona L Martin
Journal:  Orphanet J Rare Dis       Date:  2022-06-16       Impact factor: 4.303

2.  Clinical Features and Disease Course of Primary Angioedema Patients in a Tertiary Care Hospital.

Authors:  Amalie Hartvig Pall; Anne Fog Lomholt; Christian von Buchwald; Anette Bygum; Eva Rye Rasmussen
Journal:  J Asthma Allergy       Date:  2020-07-17

3.  Hereditary Angioedema with and Without C1-Inhibitor Deficiency in Postmenopausal Women.

Authors:  Aurore Billebeau; Olivier Fain; David Launay; Isabelle Boccon-Gibod; Laurence Bouillet; Delphine Gobert; Geneviève Plu-Bureau; Anne Gompel
Journal:  J Clin Immunol       Date:  2020-10-31       Impact factor: 8.317

4.  Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study.

Authors:  William R Lumry; Karsten Weller; Markus Magerl; Aleena Banerji; Hilary J Longhurst; Marc A Riedl; Hannah B Lewis; Peng Lu; Giovanna Devercelli; Gagan Jain; Marcus Maurer
Journal:  Allergy       Date:  2020-12-24       Impact factor: 13.146

Review 5.  Patient-reported Outcome Measures for Angioedema: A Literature Review.

Authors:  Anna Trier Heiberg Brix; Henrik Balle Boysen; Karsten Weller; Teresa Caballero; Anette Bygum
Journal:  Acta Derm Venereol       Date:  2021-05-19       Impact factor: 3.875

6.  The international WAO/EAACI guideline for the management of hereditary angioedema - The 2021 revision and update.

Authors:  Marcus Maurer; Markus Magerl; Stephen Betschel; Werner Aberer; Ignacio J Ansotegui; Emel Aygören-Pürsün; Aleena Banerji; Noémi-Anna Bara; Isabelle Boccon-Gibod; Konrad Bork; Laurence Bouillet; Henrik Balle Boysen; Nicholas Brodszki; Paula J Busse; Anette Bygum; Teresa Caballero; Mauro Cancian; Anthony J Castaldo; Danny M Cohn; Dorottya Csuka; Henriette Farkas; Mark Gompels; Richard Gower; Anete S Grumach; Guillermo Guidos-Fogelbach; Michihiro Hide; Hye-Ryun Kang; Allen P Kaplan; Constance H Katelaris; Sorena Kiani-Alikhan; Wei-Te Lei; Richard F Lockey; Hilary Longhurst; William Lumry; Andrew MacGinnitie; Alejandro Malbran; Inmaculada Martinez Saguer; Juan José Matta Campos; Alexander Nast; Dinh Nguyen; Sandra A Nieto-Martinez; Ruby Pawankar; Jonathan Peter; Grzegorz Porebski; Nieves Prior; Avner Reshef; Marc Riedl; Bruce Ritchie; Farrukh Rafique Sheikh; William B Smith; Peter J Spaeth; Marcin Stobiecki; Elias Toubi; Lilian Agnes Varga; Karsten Weller; Andrea Zanichelli; Yuxiang Zhi; Bruce Zuraw; Timothy Craig
Journal:  World Allergy Organ J       Date:  2022-04-07       Impact factor: 5.516

Review 7.  Disease Severity, Activity, Impact, and Control and How to Assess Them in Patients with Hereditary Angioedema.

Authors:  Anette Bygum; Paula Busse; Teresa Caballero; Marcus Maurer
Journal:  Front Med (Lausanne)       Date:  2017-12-04

8.  Letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous C1 inhibitor replacement therapy.

Authors:  John Anderson; Donald S Levy; William Lumry; Patricia Koochaki; Sally Lanar; H Henry Li
Journal:  Allergy Asthma Clin Immunol       Date:  2021-06-27       Impact factor: 3.406

9.  Safety, effectiveness, and impact on quality of life of self-administration with plasma-derived nanofiltered C1 inhibitor (Berinert®) in patients with hereditary angioedema: the SABHA study.

Authors:  Andrea Zanichelli; Giulia Maria Azin; Federico Cristina; Romualdo Vacchini; Teresa Caballero
Journal:  Orphanet J Rare Dis       Date:  2018-04-10       Impact factor: 4.123

10.  Brazilian Guidelines for Hereditary Angioedema Management - 2017 Update Part 1: Definition, Classification and Diagnosis.

Authors:  Pedro Giavina-Bianchi; Luisa Karla Arruda; Marcelo V Aun; Regis A Campos; Herberto J Chong-Neto; Rosemeire N Constantino-Silva; Fátima R Fernandes; Maria F Ferraro; Mariana P L Ferriani; Alfeu T França; Gustavo Fusaro; Juliana F B Garcia; Shirley Komninakis; Luana S M Maia; Eli Mansour; Adriana S Moreno; Antonio A Motta; João B Pesquero; Nathalia Portilho; Nelson A Rosário; Faradiba S Serpa; Dirceu Solé; Priscila Takejima; Eliana Toledo; Solange O.R Valle; Camila L Veronez; Anete S Grumach
Journal:  Clinics (Sao Paulo)       Date:  2018-05-03       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.